Blincyto (blinatumomab)

pCPA File Number: 20968
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute Lymphoblastic Leukemia (ALL), Pediatric
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
PC0099-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: